# Vergent Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vergent-bioscience

- Industry: Biotechnology
- Headquarters: Minneapolis, US
- Website: www.vergentbio.com
- Total disclosed funding: $30M
- Latest round: Series B (Aug 17, 2022)
- Investors on record: 7

## About

Vergent Bioscience develops advanced tumor-targeted fluorescent imaging agents, enhancing tumor visibility during surgeries. Their innovative solutions aim to improve surgical outcomes and patient care in oncology settings.Vergent Bioscience, Inc. is focused on creating advanced imaging solutions for surgical applications, particularly in oncology. Founded in 2016 in Minneapolis, US, by Jeff Julkowski, the company has completed 2 deals, with the most recent funding round being a Series B completed in August 2022, raising USD 21.5 mn from investors including Orlando Health Ventures and Intuitive Surgical, Inc. The total amount raised to date stands at USD 21.5 mn, with a current valuation of USD 43.997 mn.Vergent Bioscience specializes in the development of advanced tumor-targeted fluorescent imaging agents, with its lead product, abenacianine for injection (VGT-309). This imaging agent enhances tumor visibility during minimally invasive surgeries, particularly for lung cancer, and has potential applications across various solid tumors. Their products cater to surgical professionals and healthcare institutions in regions with advanced healthcare systems, such as North America and Europe, focusing on improving surgical outcomes and patient care.Vergent Bioscience generates revenue through partnerships with healthcare providers, focusing on hospitals and surgical clinics. Revenue is primarily derived from the sale of VGT-309 for surgical procedures, structured through direct sales agreements reflecting the product's clinical value and operational costs. The company emphasizes building strong relationships with surgical teams to enhance cancer treatment accessibility and effectiveness.Vergent Bioscience plans to utilize its recent Series B funding of USD 21.5 mn, raised in August 2022, to advance the clinical development of VGT-309. The company aims to expand into new markets and regions, although specific targets have not been disclosed. The funding will support ongoing research and development initiatives to enhance their product offerings in surgical oncology.

## Funding rounds

- Series B, Aug 17, 2022, $22M — Spring Mountain Capital, Windham Venture Partners, Intuitive Surgical, Inc., Orlando Health, Colle Capital, Rex Health Ventures, Orlando Health Ventures
- Series A, May 25, 2018, $8.7M — Spring Mountain Capital

## Investors

- Spring Mountain Capital (https://capitalatlas.ai/funds/spring-mountain-capital) — Series A, Series B
- Windham Venture Partners (https://capitalatlas.ai/funds/windham-venture-partners) — Series B
- Intuitive Surgical, Inc. — Series B
- Orlando Health — Series B
- Colle Capital (https://capitalatlas.ai/funds/colle-capital) — Series B
- Rex Health Ventures (https://capitalatlas.ai/funds/rex-health-ventures) — Series B
- Orlando Health Ventures — Series B